Skip to main content

Cellomics Sells ArrayScan System to Serono Pharmaceutical

NEW YORK, Oct. 2 – Cellomics of Pittsburgh said Tuesday it sold its ArrayScan High Content Screening system to Serono Pharmaceutical Research Institute, a subsidiary of Serono International of Switzerland.

Financial terms of the deal were not disclosed.

The ArrayScan HCS system analyzes how potential drugs affect cells by automatically imaging whether cellular probes fluoresce. The system, which Cellomics said has been placed in nine of the top 10 pharmaceutical companies in the world, is compatible with both 96 and 384 well microtitre plates.

"The ArrayScan HCS System will enable us to increase our efficiency, accuracy, and output of cell-based biological tests for small molecule and therapeutic protein discovery projects," Anthony Nichols, SPRI cellular pharmacology group leader, said in a statement.

Beckman Coulter is the exclusive distributor of Cellomics' ArrayScan HCS System, Cellomics' KineticScan HCS Reader, and Cellomics' Informatics Solutions.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.